Etirinotecan Pegol

Summary

Etirinotecan Pegol (CHEMBL3039558) is a phase-3 clinical-stage unknown (ATC L01CE03); indicated across 9 conditions including neoplasm and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: L01CE03
• Indications: 9 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039558
Name	Etirinotecan Pegol
Type	Unknown
Max phase	3
ATC	L01CE03

Also known as: Etirinotecan pegol, NKTR-102, ETIRINOTECAN PEGOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
breast neoplasm	3	MONDO:0021100	MONDO:0007254
glioblastoma	2	MONDO:0018177	EFO:0000519
anaplastic astrocytoma	2	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	2	MONDO:0016696	EFO:0002501
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
ovarian cancer	2	MONDO:0008170	MONDO:0008170
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01492101	PHASE3	COMPLETED	The BEACON Study (Breast Cancer Outcomes With NKTR-102)
NCT02915744	PHASE3	COMPLETED	A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician’s Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
NCT00598975	PHASE2	COMPLETED	NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
NCT00802945	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
NCT00806156	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
NCT00856375	PHASE2	COMPLETED	NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
NCT01457118	PHASE2	COMPLETED	An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
NCT01663012	PHASE2	COMPLETED	Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
NCT01773109	PHASE2	COMPLETED	Etirinotecan Pegol (NKTR-102) in NSCLC
NCT01976143	PHASE1	COMPLETED	A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).